Data on the use of convalescent plasma in the treatment of covid-19 are scarce: theresults of randomized studies involving mainly immunocompetent patients aredisappointing, while case series or retrospective data on more selected patients , inparticular immunocompromised patients suggest a benefit in these patients whose clinicalmanifestation seems essentially related to the uncontrolled infection and not thecytokine storm.
Not Provided
Inclusion criteria:
- Adult patient
- Immunocompromised patient (solid neoplasia, malignant hemopathy, solid organ
transplantation, primary immune deficiency, systemic disease, chronic inflammatory
disease, etc.)
- Hospitalized between 25/02/2020 and 15/01/2023 at HUS, ICANS, CH Colmar and CH
Mulhouse
- Having received curative monoclonal antibody treatment or convalescent plasma
treatment for SARS-Cov2 infection
- Patient who has not expressed, after being informed, his opposition to the reuse of
his data for scientific research purposes.
Exclusion criteria:
- Subject who expressed their opposition to participating in the study
- Subject under guardianship, curatorship or safeguard of justice
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France
Investigator: François DANION, MD
Contact: 33 3 69 55 15 88
francois.danion@chru-strasbourg.fr
François DANION, MD
33 3 69 55 15 88
Francois.danion@chru-strasbourg.fr
Not Provided